Kenneth L. Davis has been president and CEO of The Mount Sinai Medical System for ten years, placing the institution on a trajectory of dramatic growth. For 15 years, Davis was chair of Mount Sinai’s Department of Psychiatry and the founding director for many of the institution’s research entities. His research led to the FDA’s approval of three of the first four drugs approved for Alzheimer’s and to a revolutionary understanding of myelination, white matter, and oligodendrocytes in the pathophysiology of schizophrenia.
Kenneth L. Davis, MD
Aspen Institute Trustee, President and Chief Executive Officer, Mount Sinai Medical System